Innovation in Target Validation - Terry Fox Research Institute (Ontario Node)
The Innovation in Target Validation Program aids in the development of novel diagnostic tests to identify the best set of agents to treat each cancer patient individually. The cancer therapies prescribed could be different for each patient to maximize the effect of treatment. The program is also identifying new compounds that can selectively kill cancer cells and minimize adverse reactions.
OICR partnered with The Terry Fox Research Institute Ontario node to streamline the development of cancer therapies that target cancer cells without harming healthy ones.
Lead Principal Investigator
Dr. Robert Rottapel
Program Director, Innovation in Target Validation, Terry Fox Research Institute (Ontario Node)